Conference Coverage: ASH 2023 – Focus on Leukemia
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Aaron Logan, MD, PhD
University of California San Francisco, CA, USA
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA, USA
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology, Barcelona, Spain
REPORT SNAPSHOT
- Advances in Acute Lymphoblastic Leukemia (ALL): Newly Diagnosed
- Advances in ALL: Relapsed/Refractory
- New Developments in Myelodysplastic Syndromes (MDS)
- Advances in Acute Myeloid Leukemia (AML): Newly Diagnosed
- Advances in AML: Relapsed/Refractory
